ICICI Lombard General Insurance Allots 24,132 Equity Shares Under Employee Stock Option Schemes

ICICI Lombard General Insurance Company Limited has announced the allotment of 24,132 equity shares under its employee stock option schemes on January 13, 2026. The allotment represents the company's ongoing commitment to employee participation through equity-based compensation programs.

Share Allotment Details

The company allotted a total of 24,132 equity shares of ₹10 each across two distinct employee stock option schemes. The distribution of shares demonstrates the utilization of both legacy and contemporary employee incentive programs.

Scheme:	Shares Allotted
ICICI Lombard Employees Stock Option Scheme - 2005:	22,991
ICICI Lombard - Employees Stock Unit Scheme – 2023:	1,141
Total Shares Allotted:	24,132

Approval and Authorization

The allotment received approval from a Whole-time Director of the company on January 13, 2026 at 03:16 p.m. This approval was granted pursuant to the authority delegated by the Board of Directors at its meeting held on July 18, 2023. The structured approval process ensures compliance with corporate governance requirements for equity allotments.

Share Characteristics

The newly allotted equity shares carry a face value of ₹10 each and will rank pari-passu with the existing equity shares of the company in all respects. This means the new shares will have equal rights regarding dividends, voting, and other shareholder benefits as the existing equity shares.

Corporate Communication

The company has formally communicated this allotment to both BSE Limited and National Stock Exchange of India Limited, where its equity shares are listed under the scrip codes BSE: 540716 and NSE: ICICIGI. The information regarding this allotment is also available on the company's official website at www.icicilombard.com , ensuring transparency and accessibility for stakeholders.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.30%	-4.77%	-2.70%	-6.30%	+2.64%	+20.41%

ICICI Lombard General Insurance Company Limited has announced its financial results for the quarter and nine months ended December 31, 2025, demonstrating strong premium growth amid challenging market conditions. The company's performance reflects resilience in its core business segments while navigating regulatory changes and market dynamics.

Financial Performance Overview

The company's financial metrics for the reporting period show mixed results with strong premium growth offset by margin pressures:

Metric	Q3 FY25	Q3 FY26	Growth (%)	9M FY25	9M FY26	Growth (%)
GDPI (₹ billion)	62.14	70.41	13.3%	206.23	213.72	3.6%
PBT (₹ billion)	9.60	8.70	-9.4%	26.53	29.41	10.8%
PAT (₹ billion)	7.24	6.59	-9.1%	19.99	22.25	11.3%

Premium Growth and Market Position

The company achieved notable premium growth across different time periods. For Q3 FY26, GDPI growth of 13.3% outpaced the industry growth of 11.5%. When excluding Crop and Mass Health segments, the company's GDPI growth reached 16.4% compared to industry growth of 20.1% for the same period.

For the nine-month period, while overall GDPI growth of 3.6% lagged behind industry growth of 8.7%, the company showed stronger performance when excluding Crop and Mass Health segments, achieving 7.5% growth against industry growth of 13.3%.

Operational Metrics and Combined Ratio

The combined ratio experienced upward pressure during the reporting period:

Period	Combined Ratio (1/n basis)	Combined Ratio (n basis)
Q3 FY26	104.5%	103.1%
Q3 FY25	102.7%	102.3%
9M FY26	104.2%	103.1%
9M FY25	102.9%	102.8%

Catastrophic losses impacted the combined ratio, with ₹0.84 billion in 9M FY26 compared to ₹0.94 billion in 9M FY25. Excluding these CAT losses, the combined ratio on 1/n basis was 103.7% for 9M FY26 and 102.9% for 9M FY25.

Regulatory Impact and Adjustments

The implementation of the Code on Social Security, 2020, effective November 21, 2025, created a significant impact of ₹0.55 billion in Q3 FY26. Excluding this regulatory impact, the adjusted metrics showed improved performance:

Combined ratio on 1/n basis: 103.9% for 9M FY26 and 103.5% for Q3 FY26
Combined ratio on n basis: 102.8% for 9M FY26 and 102.2% for Q3 FY26
PAT growth excluding wage code impact: 13.4% for 9M FY26 and -3.3% for Q3 FY26 on 1/n basis

Return on Equity and Capital Efficiency

Return on Average Equity (ROAE) on 1/n basis stood at 19.5% for 9M FY26 compared to 20.8% in 9M FY25. For Q3 FY26, ROAE was 16.5% compared to 21.5% in Q3 FY25. Excluding the impact of the Wage Code, ROAE for 9M FY26 was 19.8% and 17.5% for Q3 FY26.

The company maintained strong capital gains performance with ₹9.33 billion in 9M FY26 compared to ₹7.96 billion in 9M FY25. For Q3 FY26, capital gains reached ₹3.17 billion compared to ₹2.76 billion in Q3 FY25, supporting overall profitability despite operational challenges.